UP - logo

Search results

Basic search    Advanced search   
Search
request
Library

Currently you are NOT authorised to access e-resources UPUK. For full access, REGISTER.

1 2 3 4 5
hits: 86,907
1.
  • Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
    Dev, Harveer; Chiang, Ting-Wei Will; Lescale, Chloe ... Nature cell biology, 08/2018, Volume: 20, Issue: 8
    Journal Article
    Peer reviewed
    Open access

    BRCA1 deficiencies cause breast, ovarian, prostate and other cancers, and render tumours hypersensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. To understand the resistance mechanisms, we ...
Full text

PDF
2.
  • Epithelial ovarian cancer: ... Epithelial ovarian cancer: Evolution of management in the era of precision medicine
    Lheureux, Stephanie; Braunstein, Marsela; Oza, Amit M. CA: a cancer journal for clinicians, July/August 2019, Volume: 69, Issue: 4
    Journal Article
    Peer reviewed
    Open access

    Ovarian cancer is the second most common cause of gynecologic cancer death in women around the world. The outcomes are complicated, because the disease is often diagnosed late and composed of several ...
Full text

PDF
3.
  • Standard first-line chemoth... Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
    du Bois, Andreas, Prof; Kristensen, Gunnar, Prof; Ray-Coquard, Isabelle, Prof ... The lancet oncology, 2016, January 2016, 2016-Jan, 2016-01-00, 20160101, 2016-01, Volume: 17, Issue: 1
    Journal Article, Web Resource
    Peer reviewed
    Open access

    Summary Background Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and ...
Full text
4.
  • Ovarian Cancer: An Integrat... Ovarian Cancer: An Integrated Review
    Stewart, Christine; Ralyea, Christine; Lockwood, Suzy Seminars in oncology nursing, April 2019, 2019-Apr, 2019-04-00, 20190401, Volume: 35, Issue: 2
    Journal Article
    Peer reviewed

    To provide an overview of the risk factors, modifiable and non-modifiable, for ovarian cancer as well as prevention, diagnostic, treatment, and long-term survivorship concerns. This article will also ...
Full text
5.
  • The origin and pathogenesis... The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory
    Kurman, Robert J; Shih, Ie-Ming The American journal of surgical pathology, 03/2010, Volume: 34, Issue: 3
    Journal Article
    Peer reviewed
    Open access

    Ovarian cancer is the most lethal gynecologic malignancy. Efforts at early detection and new therapeutic approaches to reduce mortality have been largely unsuccessful, because the origin and ...
Full text

PDF
6.
  • Final results from GCIG/ENG... Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer
    Ray‐Coquard, Isabelle; Cibula, David; Mirza, Mansoor R. ... International journal of cancer, 15 January 2020, Volume: 146, Issue: 2
    Journal Article, Web Resource
    Peer reviewed
    Open access

    AGO‐OVAR 12 investigated the effect of adding the oral triple angiokinase inhibitor nintedanib to standard front‐line chemotherapy for advanced ovarian cancer. At the primary analysis, nintedanib ...
Full text
7.
  • Heterogeneous Tumor-Immune ... Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient
    Jiménez-Sánchez, Alejandro; Memon, Danish; Pourpe, Stephane ... Cell, 08/2017, Volume: 170, Issue: 5
    Journal Article
    Peer reviewed
    Open access

    We present an exceptional case of a patient with high-grade serous ovarian cancer, treated with multiple chemotherapy regimens, who exhibited regression of some metastatic lesions with concomitant ...
Full text

PDF
8.
  • Morphologic, Immunophenotyp... Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer
    Ramalingam, Preetha Oncology (Williston Park, N.Y.), 02/2016, Volume: 30, Issue: 2
    Journal Article
    Peer reviewed

    Epithelial ovarian cancer comprises a heterogeneous group of tumors. The four most common subtypes are serous, endometrioid, clear cell, and mucinous carcinoma. Less common are transitional cell ...
Check availability
9.
  • Olaparib combined with chem... Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
    Oza, Amit M, Prof; Cibula, David, Prof; Benzaquen, Ana Oaknin, MD ... The lancet oncology, 2015, January 2015, 2015-Jan, 2015-01-00, 20150101, Volume: 16, Issue: 1
    Journal Article
    Peer reviewed

    Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer with or without ...
Full text
10.
  • Epidemiology of epithelial ... Epidemiology of epithelial ovarian cancer
    Webb, Penelope M; Jordan, Susan J Best practice & research. Clinical obstetrics & gynaecology, 05/2017, Volume: 41
    Journal Article
    Peer reviewed

    Abstract Globally, ovarian cancer is the seventh most common cancer in women and the eighth most common cause of cancer death, with five-year survival rates below 45%. Although age-standardised rates ...
Full text

PDF
1 2 3 4 5
hits: 86,907

Load filters